Cancer Genetics — Q2 2018 Earnings Presentation
10 slides from Cancer Genetics's earnings presentation, Aug 14, 2018
Slide 1: Cancer Genetics Incorporated: Empowering Personalized Cancer Treatment
CANCER GENETICS INCORPORATED Empowering Personalized Cancer Treatment webcast link: http://public. viavid.com/index.php?id=130945
Slide 2: Forward-Looking Statements
p.2) Gi Forward-Looking Statements These slides may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in revenues, margins, research, technology, clinica
Slide 3: Everything We Do Is Focused on 1 Key Idea
EVERYTHING WE DO IS FOCUSED ON 1 KEY IDEA... ..-DELIVER INNOVATION & PATIENT VALUE BY PROVIDING THE MOST COMPREHENSIVE CAPABILITIES FOR PRECISION ONCOLOGY DEVELOPMENT.
Slide 4: Revenue & Growth Highlights
Gi Revenue & Growth Highlights p.4 | 2ND QUARTER REVENUE 187 HALF YEAR REVENUE FULL YEAR REVENUE $29.0M $7.0M E $27.0M $6.6M 4-Year CAGR 30” c13.0m $10.2M Q22014 Q2 2015 Q2 2016 Q2 2017 Q2 2018 1H 2014 1H 2015 1H 2016 1H 2017 1H 2018 2014 2015 2016 2017 Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2018
Slide 5: Revenues by Market & Customer Category
Gi Revenues by Market & Customer Category p.> | $3.6M || BIOPHARMA SERVICES = Supports 249 clinical trials and studies focused on Solid Tumor and Blood Cancers, including 53 for immuno-oncology indications. CLINICAL SERVICES = Over 16,400 tests performed in Q2 2018. Comprehensive test portfolio incl
Slide 6: Q2 2018 and Recent Operational Highlights
Gi Q2 2018 and Recent Operational Highlights p.0 | « Strengthened leadership team with appointment of Michael McCartney as Chief Commercial Officer. + Raised $2.5 million through a convertible note financing. + Raised $1.9 million in April 2018 by the sale of a non-core asset (wholly-owned subsidiar
Slide 7: Q2 2018 Financial Highlights
Gi Q2 2018 Financial Highlights p.7 | « Revenues of $7.0 million, 6% increase or $0.4 million over $6.6 million in Q2 2017. » Biopharma Services revenue totaled $3.6 million compared to $3.3 million in Q2 2017. = Clinical Services revenue totaled $2.1 million compared to $3.1 million in Q2 2017. Thi
Slide 8: Summary Statement of Operations
p.8 | Summary Statement of Operations Gi Income Statement Items Q2 2018 Q2 2017 1H 2018 1H 2017 ($ in Thousands) Revenue $7,036 $6,604 $14,703 $13,570 Gross Profit $2,183 $2,570 $4,768 $5,327 Gross Margin (%) 31% 39% 32% 39% Research & Development (R&D) $673 $989 $1,354 $2,099 Sales & Marketing (S&M
Slide 9: Biotech and Pharma Highlights: Strong Year over Year & Quarterly Progress
Biotech and Pharma Highlights: Strong Year over Year & Quarterly Progress pg] ANNUAL PROGRESS QUARTERLY PROGRESS TOTAL ACTIVE PROJECTS aa 342 250 308 300 oa 67 200 170 a 241 100 50 Q2 2017 Q1 2018 Q2 2018 2-fold increase in biopharma projects from 170 to 342 projects 11% increase in biopharma projec
Slide 10: Cancer Genetics Incorporated locations
INCORPORATED (aang _ ( Csi GENETICS a , Poe s 4 a wh a ” . ¥ - f ie er ae US Pa ye : HERSHEY, PA, USA Pr » SF ak aed 4214 Research Boulevard y J " “ww Hummelstown, PA 0. on “ Ad «* 17036 3 =f, Pt a Bi 373-2243 "Phone: +1 717-798-9990 ~~. y A : e MUNICH, GERMANY ‘ OURNE, AUSTRALIA